Enabling highest standards in product potency validation.
On demand scientific validation of new products.
Data package consistent with DEA and FDA requirements.
Stronger product claims backed by the ability to determine product therapeutic applications through mechanism of action testing.
Preferred by strategic partners by supplying consistent products batch-to-batch through cell-based potency validation.
First to market and greater market share through data-driven credibility.
Other than Cannabinoid and terpene chemical compositional analysis and inferences of
potency therefrom, there has been little to no effort in the industry to validate products for
their actual biological potency using biomarkers within the endocannabinoid system. For the
non-psychotropic cannabinoids and terpenes, percent composition cannot predict how the
human endocannabinoid system will respond to individual purified Cannabinoids and
certainly cannot predict how multiple agonist and antagonist compounds within broad or full
spectrum products might affect patients. The industry needs to adopt the standards
comparable to how drug potency is measured and expressed throughout the pharmaceutical
industry, namely, units of activity per drug concentration (i.e. biological potency) as well as
chemical composition. CannaMetrix addresses this unmet need through proprietary human
cell-based potency testing that will establish a new high bar for the industry in Cannabis
products development and product validation.
Differentiate products by their dose-dependent potency in human cells along defined cannabinoid receptor pathways that better predicts medicinal product indications.
Transform the medicinal cannabis industry with pharmaceutical standards for product potency validation and for product consistency testing using a novel human cell-based testing that will empower products with competitive market opportunities.
National and international sales will be based on both fee-for-service testing and through nonexclusive or exclusive licensing agreements for the patent-pending technology.
Establish exclusive agreements with a strategic partner seeking proprietary methods to calibrate and vet their development of new strains of Cannabis for targeting specific treatments for humans or pets and accelerate regulatory approval.
Producers and patients will pay for advanced testing because it informs consumer and doctors of choices especially in states and countries where full spectrum products are marketed for medicinal applications.
